Absorption of colesevelam hydrochloride in healthy volunteers

Annals of Pharmacotherapy

Volumn 36, Issue 3, 2002, Pages 398-403

  Heller, Dennis P ^a   Burke, Steven K ^a   Davidson, David M ^b   Donovan, Joanne M ^b  

^a Marketing and Business Development   (United States)

^b GelTex Pharmaceuticals   (United States)

Author keywords

Absorption; Colesevelam; Sequestrant

Indexed keywords

CARBON 14; COLESEVELAM;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG FECES LEVEL; DRUG URINE LEVEL; FEMALE; GASTROINTESTINAL ABSORPTION; HUMAN; ISOTOPE LABELING; MALE; NORMAL HUMAN; PRIORITY JOURNAL; URINARY EXCRETION;

ALLYLAMINE; FECES; HUMANS; INTESTINAL ABSORPTION;

EID: 0036195952     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A143     Document Type: Article

References (47)

1. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study
2. Relationship between plasma lipid concentrations and coronary artery disease in 496 patients
3. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men
4. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study
5. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study
6. Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial
7. Plasma cholesterol concentration and mortality. The Whitehall Study
8. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations
9. The Münster heart study (PROCAM). Results of follow-up at 8 years
10. Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study
11. Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT])
12. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol
13. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
14. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
15. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
16. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
17. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/Tex-CAPS
18. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)
19. 14
20. 14C]colestipol hydrochloride and its disposition in the human, dog and rat
21. Role of the enterohepatic circulation of bile salts in lipoprotein metabolism
22. Bile acid sequestrants: Mechanisms of action on bile acid and cholesterol metabolism
23. A receptor-mediated pathway for cholesterol homeostasis
24. Evaluation of the effectiveness of lipidlowering therapy (bile acid sequestrants, niacin, psyllium and lovastatin) for treating hypercholesterolemia in veterans
25. The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease of cholesterol lowering
26. Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy
27. In vitro comparison of bile acid binding to colesevelam HCl and other bile acid sequestrants
28. Colesevelam hydrochloride (cholestagel): A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects
29. Low dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low density lipoprotein cholesterol in patients with primary hypercholesterolemia
30. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively
31. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia
32. Drug interactions of colesevelam hydrochloride, a novel potent bile acid binding polymer
33. Metabolic disposition of simvastatin in patients with T-tube drainage
34. 14C-labeled afovirsen sodium in patients with genital warts
35. Fluoxetine: Clinical pharmacology and physiologic disposition
36. The lipid treatment assessment project (L-TAP)
37. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels: A randomized, placebo-controlled trial
38. Recommended management for hyperlipidemia and heart failure: Are we following the guidelines?
39. The Lipid Research Clinics Coronary Primary Prevention Trial. Results of 6 years of post-trial follow-up
40. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia
41. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia
42. Comparative efficacy of colestipol and clofibrate in type IIa hyperlipoproteinemia
43. Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine
44. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia
45. The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia
46. Simvastatin and cholestyramine in the long-term treatment of hypercholesterolaemia
47. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy